Summary by Futu AI
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's submission has become effective as of May 2, 2024. The submission, identified by accession number 0001214659-24-007804 and file number 333-272693, was categorized under the submission type POS AM. This notice of effectiveness by the SEC is a significant regulatory milestone for Biodexa Pharmaceuticals.